Journal of the Korean Society of Radiology (한국방사선학회논문지)

The Korean Society of Radiology (한국방사선학회)
권호 표지
DOI QR코드

DOI QR Code

A Study of Clinical Model for Radiation Therapy in Lung Cancer Patients of Busan and South Gyeongnam Province

부산, 경남지역 폐암 환자의 방사선치료 이용에 대한 임상 결정 모델 연구

  • Son, Jongki (Dept. of Hospital Radiation Oncolog at Pusan National University) ;
  • Kim, Yunjin (Dept. of Family Medicin at Pusan National University) ;
  • Jo, Deokyoung (Dept. of Medical Business at Pusan National University)
  • 손종기 (부산대학교병원 방사선종양학과) ;
  • 김윤진 (부산대학교병원 가정의학교실) ;
  • 조덕영 (부산대학교병원 의료경영학교실)
  • Received : 2015.09.14
  • Accepted : 2015.10.25
  • Published : 2015.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Radiation therapy for lung cancer is an effective treatment during monotherapy or combination therapy. Studies have reported that the optimum utilization rate of radiation therapy is estimated at 61% to 74%. Radiation therapy in Korea has been investigated to be low; further studies are needed. This study was intended to assess the appropriateness of the use of radiation and to reveal the use of radiation therapy-related factors by examining radiation therapy in lung cancer patients of Busan and South Gyeongnam Province. This study was aimed at the population diagnosed with lung cancer in Busan and South Gyeongnam Province. To conduct the study, 1036 patients enrolled in two hospitals were collected and 897 appropriate as subjects were selected. We compared the optimum utilization rate and actual rate of radiation therapy, and revealed the adequacy and related factors for use of radiotherapy. Of 897 patients, 503 (56%) were treated with medical therapy and 394 (44%) were given radiotherapy. The radiotherapy utilization rate of all lung cancer patients was 42%. The proportion of non-small cell lung cancer by histologic type was 33% and that of small cell lung cancer was 90%. Factors related to radiation therapy used in cancer were age, histological type, clinical stage, doctor refereed to, and clinical examination. Compared to radiation utilization by region (site), curative chest therapy was 42%; palliative treatment was 26%. In the comparison of histologic types, utilization of small-cell lung cancer is lower; the lowest especially in the stage III. Utilization of radiation therapy in Busan and South Gyeongnam Province was lower than the reasonable one. Utilization difference could be explained by patient factors, tumor factors, and health service factors. To improve utilization,development ofoutreach service programs and activation of the multidisciplinary team are required.

폐암에 대한 방사선치료는 단독치료 또는 병용치료 시에 효과적인 치료이다. 연구에 의하면 최적의 방사선치료 이용률은 61%에서 74% 범위로 추정되고 있으나, 우리나라의 방사선치료 이용률은 낮은 것으로 조사되어 이에 대한 연구가 필요하다. 본 연구는 부산, 경남 지역에서 폐암환자의 방사선치료 이용률을 조사하여 방사선 이용의 적절성을 평가하고 방사선치료 이용관련 인자를 밝히고자 하는 것이다. 본 연구는 폐암으로 진단된 부산, 경남 지역 인구를 대상으로 하였다. 연구를 위하여 2개의 병원에 등록된 환자 1,036명의 환자 자료를 수집하여 최종적으로 연구에 적합한 897명을 대상으로 연구를 수행하였다. 연구는 적정 이용비율과 실제 방사선치료 비율을 비교하였고, 방사선치료 이용의 적정성과 관련인자를 확인하고자 하였다. 연구대상자 897명 중에서 503명(56%)은 내과적 치료가 시행되었고, 394명 (44%)는 방사선치료가 시행되었다. 전체 폐암환자의 방사선치료 이용률은 42%이었다. 조직학적 분류에 의한 비소세포 폐암의 비율은 33%이었고, 소세포 폐암은 90%이었다. 폐암의 방사선치료 이용과 관련 인자는 연령, 조직학적 유형, 임상병기, 의뢰의사, 임상검사이었다. 부위(site)별 방사선치료 이용률을 비교했을 때 근치적 흉부치료는 42%이었고, 완화적 치료는 26%이었다. 조직학적 유형의 비교에서 소세포 폐암의 이용률은 낮았고 특히 병기 III기에서 이용률은 가장 낮았다. 부산, 경남지역에서 방사선치료의 이용률은 적정한 이용률 보다 낮게 나타났다. 이용률 차이는 환자요인, 종양요인, 의료 서비스 요인으로 설명할 수 있었다. 이용률 개선을 위해서는 아웃리치 서비스(outreach service) 프로그램의 개발과 다 학제적 팀의 활성화가 필요하다.

Keywords

References

  1. "Annual report of cancer statistics in Korea in 2012", Ministry of Health and Welfare. Korea Central Cancer Registry, National Cancer Center, 2012.
  2. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, "Lung cancer In AJCC Cancer Staging Manual. 7th edition", Edited by American Joint Committee on Cancer (AJCC). New York: Springer-Verlag, 299-323, 2010.
  3. Solda F, Lodge M, Ashley S, "Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; Systematic review and comparison with a surgical cohort", Radiotherapy and Oncology, 109:1-7, 2013. https://doi.org/10.1016/j.radonc.2013.09.006
  4. Langendijk JA, ten Velde GPM, Aaronson NK, "Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study", Int J Radiat OncolBiol Phys, 47, 149-155, 2000. https://doi.org/10.1016/S0360-3016(99)00540-4
  5. Von Dincklage JJ, Ball D, Silvestri GA, "A review of clinical practice guidelines for lung cancer", J Thorac Disease,(suppl 5), 5, S607-S622, 2013.
  6. Tyldesley S, Boyd C, Schulze K, "Estimating the need for radiotherapy for lung cancer: an evidence-based epidemiologic approach", Int J Radiat Oncol Biol Phys, 49, 973-985, 2001. https://doi.org/10.1016/S0360-3016(00)01401-2
  7. The Cancer Council Australia, "Clinical Practice Guidelines for the Prevention, Diagnosis and Management of Lung Cancer. Canberra, New South Wales", Australia: National Health and Medical Research Council, 2004.
  8. Ontario Cancer Treatment and Research Foundation, "A plan for radiation treatment, province of Ontario", 1995-2000.
  9. Koning CC, Aarts MJ, Struikmans H, "Mapping use of radiotherapy for patients with non-small cell lung cancer in the Netherlands between 1997 and 2008", Clin Oncol (R Coll Radiol), 24, e46-e53, 2012. https://doi.org/10.1016/j.clon.2011.06.010
  10. Delaney G, Barton M, Jacob S, "A model for decision making for the use of radio- therapy in lung cancer", Lancet Oncol, 4, 120-128, 2003 https://doi.org/10.1016/S1470-2045(03)00984-7
  11. Barbera L, Zhang-Salomons J, Huang J, Tyldesley S, Mackillop W, "Defining the need for radiotherapy for lung cancer in the general population: a criterion-based,benchmarking approach", Med Care, 41:1074-1085, 2003. https://doi.org/10.1097/01.MLR.0000083742.29541.BC
  12. Oken MM, Creech RH, Tormey DC, et al, "Toxicity and response criteria of the Eastern Cooperative Oncology Group", Am J Clin Oncol 5, 649-655, 1982 https://doi.org/10.1097/00000421-198212000-00014
  13. Shalini K. Vinod, MBBS, MD, FRANZCR, "Underutilization of Radiotherapy for Lung Cancer in New South Wales", Australia. Cancer, pp. 686-694. 2010.
  14. london cancer alliance, "LCA Lung Cancer Clinical Guidelines December",[.nhs.uk], 2013
  15. Clinical Guide line of the lung cancer,"Korean Association for the Study of Lung Cancer(2nd ed)", 2011.
  16. Goffin J Lacchetti C, Ellis PM, Ung YC, "Evans WK: Fist-line chemotherapy in the treatment of advanced non-small cell lung cancer. A systematic review", J ThoracOncol, 5, 260-274, 2010.
  17. Laroche C, Wells F, Coulden R. Improving surgical resection rate in lung cancer. Thorax, 53, 445-449, 1998. https://doi.org/10.1136/thx.53.6.445
  18. Ball DL, Fisher R, Burmeister B, "Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database", J Thorac Oncol1, 667-672, 2006.
  19. Hayman JA, Abrahamse PH, Lakhani I, "Use of palliative radiotherapy among patients with metastatic non-small-cell lung cancer", Int J Radiat Oncol Biol Phys, 69, 1001-1007, 2007. https://doi.org/10.1016/j.ijrobp.2007.04.059
  20. Erridge SC, Thomson CS, Davidson J, "Scottish Cancer Trials Lung Group and The Scottish Cancer Therapy Network. Factors influencing the use of thoracic radiotherapy in lung cancer--an analysis of the 1995 Scottish lung cancer audit", Clin Oncol (R Coll Radiol), 14, 219-227, 2002. https://doi.org/10.1053/clon.2001.0046
  21. Stevens G, Stevens W, Purchuri S, "Radiotherapy utilization in lung cancer in New Zealand: disparities with optimal rates explained", NZ Med J, 122, 43-54, 2009.
  22. Vinod SK, Barton MB, "Actual versus optimal utilization of radiotherapy in lung cancer: Where is the shortfall?", Asia-Pacific J Clin Oncol, 3, 1-7, 2007. https://doi.org/10.1111/j.1743-7563.2006.00086.x
  23. Tyldesley S, Zhang-Salomons J, Groome PA, "Association between age and the utilization of radiotherapy in Ontario", Int J Radiat Oncol Biol Phys, 47, 469-480, 2000. https://doi.org/10.1016/S0360-3016(00)00440-5
  24. Erridge SC, Murray B, Price A, "Improved treatment and survival for lung cancer patients in South-East Scotland", J Thorac Oncol, 3, 491-498, 2008. https://doi.org/10.1097/JTO.0b013e31816fca46
  25. Laroche C, Wells F, Coulden R, "Improving surgical resection rate in lung cancer", Thorax, 53, 445-449, 1998. https://doi.org/10.1136/thx.53.6.445
  26. Wassenaar TR, Eick hoff JC, Jarzemsky D, "Differences inprimary care clinicians' approach to non-small cell lung cancer patients compared with breast cancer", J Thorac Oncol, 2, 722-728, 2007. https://doi.org/10.1097/JTO.0b013e3180cc2599
  27. Erridge SC, Thomson CS, Davidson J, "Scottish Cancer Trials Lung Group and The Scottish Cancer Therapy Network. Factors influencing the use of thoracic radiotherapy in lung cancer an analysis of the 1995 Scottish lung cancer audit", Clin Oncol (R Coll Radiol), 14, 219-227, 2002. https://doi.org/10.1053/clon.2001.0046
  28. Firat S, Byhardt RW, Gore E, "The effects of comorbidity and age on RTOG study enrollment in Stage III non-small cell lung cancer patients who are eligible for RTOG studies", Int J Radiat Oncol Biol Phys, 78, 1394-1399, 2010. https://doi.org/10.1016/j.ijrobp.2009.09.051